The International Swine Flu Conference addressed best practices to prepare for, respond to, and survive a pandemic. Participants focused on the expected infection rates for the coming flu season and efforts to produce and distribute a vaccine.
ABC Boston discusses Replikins synthetic peptide H1N1 vaccine, produced in 7 days, is available now for testing worldwide. Replikins developed the vaccine based on the same peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way
Boston, November 27, 2009 - Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus... Read more
Boston, October 19, 2009 - There is increasing evidence that, with best intent, current biological technology cannot supply the world's six billion humans, and animal populations, with vaccines against emerging diseases at a rate that can contend with a disease's rapid appearance and change... Read more